Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...

Answer ALS, a large-scale research initiative headquartered in New Orleans and Washington, D.C., has announced the launch of ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation ...

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

The new drug forces fat cells to produce more energy and doesn't impact appetite or muscle mass, unlike some existing ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...